Blog

India-UK Defence Collaboration Introduction India and the United Kingdom have signed multiple agreements aimed at enhancing bilateral defence collaboration. Key Agreements and Collaborations in India-UK Defence Partnership Defence Partnership–India (DP-I):  The UK’s Ministry of Defence has established a dedicated programme office aimed at serving as a centralized hub for bilateral defence collaboration, promoting deeper cooperation and fostering economic growth in both nations. Laser Beam Riding MANPADs (LBRM):  India and the UK have entered into a contract for the procurement of Laser Beam Riding Man Portable Air Defence Systems (MANPADS). The initial delivery of High Velocity Missiles (STARStreak) and associated launchers is scheduled for this year. Lightweight Multirole Missiles (LMM):  This initiative seeks to integrate Indian and British industries into the global defence supply chain, enhancing collaborative efforts in missile technology. Advanced Short-Range Air-to-Air Missile (ASRAAM):  A partnership has been established to create an assembly and testing facility for the ASRAAM missile in Hyderabad, promoting local manufacturing capabilities. Integrated Full Electric Propulsion (IFEP) System:  A Statement of Intent was signed to design and develop an Integrated Full Electric Propulsion (IFEP) system for India’s forthcoming Landing Platform Dock (LPD) fleet. Both nations are also aiming to create India’s inaugural maritime Land-Based Testing Facility, with objectives to deploy the LPD by 2030. Key Challenges India-UK defence cooperation has faced obstacles due to the ‘three-I’ challenge, which includes: Foreign Investment regulations Intellectual Property Rights concerns Indigenous Content Requirements The agreements signify a crucial advancement in India-UK defence collaboration, particularly in essential domains like air defence and maritime propulsion. They align with India’s Atmanirbhar Bharat (self-reliant India) initiative, emphasizing the enhancement of indigenous defense capabilities and technological progress. Q: Which of the following factors has posed a challenge to India-UK defense cooperation? Currency Exchange Rates The ‘three-I’ challenge: Foreign Investment, Intellectual Property Rights, and Indigenous Content Requirements Language Barriers Geographical Distance Answer: B) The ‘three-I’ challenge: Foreign Investment, Intellectual Property Rights, and Indigenous Content Requirements India’s Pharmaceutical Exports Set for 10x Growth Introduction India’s pharmaceutical exports are anticipated to soar to $350 billion by 2047, representing a 10-15 times increase from current levels. Overview of India’s Pharmaceutical Industry Recognized internationally as the “Pharmacy of the World,” India’s pharmaceutical industry has played a pivotal role in supplying vaccines, essential medicines, and medical supplies during the COVID-19 pandemic and continues to do so. The sector has demonstrated significant innovative capabilities, solidifying its position as a vital component of the global pharmaceutical value chain. Current Global Market Status India stands as the largest global supplier of generic drugs, contributing 20% to worldwide sales. India ranks third in terms of drug and pharmaceutical production by volume. Exports span approximately 200 countries and territories. The primary export destinations include the USA, Belgium, South Africa, the UK, and Brazil. Despite being a key global player in generics, India ranks 11th in terms of pharmaceutical export value. The total annual turnover of pharmaceuticals in FY24 was ₹4.17 lakh crore, reflecting an average growth rate of 10.1% over the past five years. Export Projections India’s pharmaceutical exports are expected to rise from $27 billion in 2023 to $65 billion by 2030. This growth is anticipated to shift from volume-based to value-driven strategies, focusing on key areas such as Active Pharmaceutical Ingredients (APIs), biosimilars, and specialty generics. Active Pharmaceutical Ingredients (API): India’s API exports are projected to grow from $5 billion to $80-90 billion by 2047.Global supply chain diversification, particularly in light of the U.S. Biosecure Act, presents an opportunity for India to bolster API production. Biosimilars: Current biosimilar exports are valued at $0.8 billion, with expectations to increase fivefold to $4.2 billion by 2030, and to $30-35 billion by 2047. This growth will be supported by enhanced R&D, regulatory simplifications, and capacity expansions. Biosimilars are medications that closely resemble biologic drugs created through living systems, showcasing comparable structure and functionality. Generic Formulations: Accounting for 70% of India’s pharmaceutical exports, generic formulations are valued at $19 billion. These exports are projected to grow to $180-190 billion by 2047, with a notable shift towards higher-margin specialty generics. Policy and Strategic Measures The Indian government has initiated several programs to promote the pharmaceutical sector and stimulate investment: In September 2020, the Production Linked Incentive (PLI) scheme was introduced for the pharmaceutical sector as part of the Self-Reliant India initiative, with a budget of ₹15,000 crore allocated from 2020-2021 to 2028-29. Targeted policy measures are vital, including strengthening the API industry, addressing export barriers, and developing country-specific export strategies. India supplies 55-60% of UNICEF’s vaccines but should aim to expand its presence in high-value markets through clinical trials and manufacturing investments. Key enablers for growth include regulatory harmonization, expansion of PLI, and R&D incentives. Challenges India faces several obstacles, including issues related to intellectual property rights and limited R&D capabilities. It is crucial to understand the political, economic, sociocultural, technological, environmental, and legal factors when assessing the opportunities and challenges within the Indian pharmaceutical market. Conclusion and Future Outlook As a global leader in generic drug supply, India aims to ascend the value chain by focusing on specialty generics, biosimilars, and innovative products. This strategic shift could position India among the top five nations in export value by 2047. With aspirations to become the “healthcare custodian of the world,” the nation is prioritizing innovation, R&D, and regulatory improvements. Collaboration between academia, industry, and government will be essential in establishing a robust, globally competitive pharmaceutical sector. Q) Which of the following statements is TRUE regarding India’s position in the global pharmaceutical market? India ranks first in terms of pharmaceutical export value. India is the largest global supplier of generic drugs, accounting for 20% of global sales. India does not export pharmaceuticals to many countries. India ranks fourth in drug production by volume. Answer: B) India is the largest global supplier of generic drugs, accounting for 20% of global sales. 63rd session of the Commission for Social Development (CSoCD) India participated in the 63rd session of the Commission for Social Development (CSoCD) held from February 10 to 14,